tiprankstipranks
AstraZeneca says Tagrisso showed ‘strong’ overall survival benefit in trial
The Fly

AstraZeneca says Tagrisso showed ‘strong’ overall survival benefit in trial

AstraZeneca announced "positive" high-level results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival, or OS, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, after complete tumor resection with curative intent. In May 2020, AstraZeneca announced Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival, or DFS, in this setting. In September 2022, updated results demonstrated a median DFS of nearly five and a half years. Per the ADAURA trial protocol, patients on placebo that recurred with metastatic disease had the opportunity to receive open-label Tagrisso, the company said.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on AZN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles